Polar Capital Healthcare Opports I Inc
Healthcare and BiotechnologyPricing frequency
Daily
Dealing cut off time
13:45
Type
OEIC
Yield
–
NAV
$99.86
Income frequency
Annually
Ongoing charge
1.1%
Latest actual NAV date
13-11-2026
ISIN
IE00B3K93X10
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 30/09/2026 | % of assets |
|---|---|
| Eli Lilly and Co | 8.30 |
| Enliven Therapeutics Inc | 6.99 |
| Teva Pharmaceutical Industries Ltd | 6.47 |
| argenx SE | 6.12 |
| Novartis AG Registered Shares | 5.83 |
| Johnson & Johnson | 5.14 |
| Torrent Pharmaceuticals Ltd | 4.87 |
| Abbott Laboratories | 4.44 |
| Edwards Lifesciences Corp | 3.42 |
| Uniphar PLC | 3.27 |
Investment objective
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies. The Fund will at all times invest at least two thirds of its total assets (excluding cash) in healthcare-related companies worldwide. The Fund will invest at least 51% of its gross assets on a continuous basis directly in Equity Participations. Subject to the investment restrictions described in Appendix II of the Prospectus, investments will be made in transferable securities including, but not limited to, shares, equity warrants and other types of securities such as preferred shares, which may be listed on a Regulated Market or unlisted, and issued by companies, and Global, American and European depository receipts. The Fund may not invest more than 10% of its Net Asset Value in unlisted securities.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.